Research Topics
| J ArmitageSummaryAffiliation: University of Oxford Country: UK Publications
| Collaborators
|
Detail Information
Publications
Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemiaJ Armitage
Clinical Trial Service Unit, Richard Doll Building, Old Road Campus, University of Oxford, Oxford OX3 7LF, UK
Heart 94:643-5. 2008- The impact of privacy and confidentiality laws on the conduct of clinical trialsJane Armitage
Clin Trials 5:70-4. 2008..The negative impact of privacy legislation on the use of personal health information and on conducting large studies needs to be understood and minimized... - The safety of statins in clinical practiceJane Armitage
Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK
Lancet 370:1781-90. 2007..For most people, statins are safe and well-tolerated, and their widespread use has the potential to have a major effect on the global burden of cardiovascular disease... - Cardiovascular outcomes among participants with diabetes in the recent large statin trialsJane Armitage
Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Oxford, UK
Curr Opin Lipidol 15:439-46. 2004..Here we review the results of recent randomized trials, which included substantial numbers of patients with diabetes and no vascular disease... - Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementiaRobert Clarke
Clinical Trial Service Unit, University of Oxford, Oxford, UK
Curr Opin Clin Nutr Metab Care 10:32-9. 2007..Dietary supplementation with folic acid and vitamin B12 lowers blood homocysteine concentrations, but it is not known if this reduces the risk of coronary heart disease and stroke... - Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysisR Clarke
Clinical Trial Service Unit, University of Oxford, Oxford, UK
Clin Chem Lab Med 45:1575-81. 2007.... - Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplementsR Clarke
Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, England
Semin Thromb Hemost 26:341-8. 2000..Large-scale randomized trials of such regimens are now required to determine whether lowering homocysteine levels by folic acid and vitamin B12, with or without added vitamin B6, reduces the risk of vascular disease... - First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney diseaseColin Baigent
Clinical Trial Service Unit, Oxford University, Oxford, UK
Am J Kidney Dis 45:473-84. 2005..Patients with chronic kidney disease are at increased risk for cardiovascular disease, but the efficacy and safety of simvastatin and aspirin are unknown in this patient group... - Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection StudyJemma C Hopewell
Clinical Trial Service Unit, University of Oxford, Oxford, England
Circ Cardiovasc Genet 4:68-73. 2011.... - Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individualsRobert Clarke
University of Oxford, England
Arch Intern Med 170:1622-31. 2010..Dietary supplementation with folic acid to lower homocysteine levels had no significant effects within 5 years on cardiovascular events or on overall cancer or mortality in the populations studied... - Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servantsRobert Clarke
Clinical Trial Service Unit and Epidemiological Studies Unit CTSU, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX37LF, UK
Br J Nutr 102:279-84. 2009.... - High-risk elderly patients PROSPER from cholesterol-lowering therapyRory Collins
Clinical Trial Service Unit and Epidemiological Studies Unit, Harkness Building, Radcliffe Infirmary, OX2 6HE, Oxford, UK
Lancet 360:1618-9. 2002 - Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trialsRobert Clarke
Clinical Trial Service Unit, Radcliffe Infirmary, Oxford OX2 6HE, UK
Cardiovasc Drugs Ther 16:411-5. 2002..The results of these trials have been disappointing and failed to confirm any protective effect of these vitamins for either cancer or for cardiovascular disease... - Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older menRobert Clarke
Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, England
Arch Intern Med 167:1373-8. 2007..The relevance of blood lipid levels as risk factors for ischemic heart disease (IHD) in older people is uncertain; hence, cholesterol-lowering therapy is not routinely prescribed in older populations... - The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKDMartin Landray
Clinical Trial Service Unit, University of Oxford, Churchill Hospital, Oxford, UK
Am J Kidney Dis 47:385-95. 2006..In preparation for such a trial, we assessed the biochemical efficacy, safety, and tolerability of adding ezetimibe, 10 mg/d, to simvastatin, 20 mg/d, as initial therapy for such patients... - N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection studyJonathan R Emberson
Clinical Trial Service Unit, University of Oxford, UK
J Am Coll Cardiol 49:311-9. 2007..We sought to assess the ability of N-terminal pro-B-type natriuretic peptide (N-BNP) to predict vascular events in high-risk people and to test whether statins benefit people with high levels of N-BNP... - Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular riskLouise Bowman
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Medicine, Radcliffe Infirmary, Oxford, United Kingdom
Semin Vasc Med 2:383-9. 2002..Randomized evidence for glucose lowering is not as conclusive, but it seems likely that glucose control should be treated in a similar manner... - Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trialJane Armitage
SEARCH Study, Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK
Lancet 376:1658-69. 2010..We aimed to establish efficacy and safety of more intensive statin treatment in patients at high cardiovascular risk... - The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialColin Baigent
Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
Lancet 377:2181-92. 2011..The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients... - The MRC/BHF Heart Protection Study: preliminary resultsRory Collins
Oxford Clinical Trials Service Unit
Int J Clin Pract 56:53-6. 2002..Nevertheless, results were highly significant for the study statin--simvastatin 40 mg once daily. Preliminary results of the HPS are negative for the antioxidant vitamin cocktail but provide reassurance that vitamins do no harm... - Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 peopleBorislava Mihaylova
BMJ 333:1145. 2006..CONCLUSIONS: Treatment with statins is cost effective in a wider population than is routinely treated at present... - Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditionsRory Collins
Lancet 363:757-67. 2004..HPS also provides definitive evidence that statin therapy is beneficial for people with pre-existing cerebrovascular disease, even if they do not already have manifest coronary disease... - Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individualsBorislava Mihaylova
Lancet 365:1779-85. 2005..It would be appropriate to consider reducing the estimated level of vascular event risk at which statin therapy is recommended... - MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialRory Collins
Lancet 361:2005-16. 2003..Statin therapy should now be considered routinely for all diabetic patients at sufficiently high risk of major vascular events, irrespective of their initial cholesterol concentrations...